Literature DB >> 20519625

Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement.

Amudhan Maniar1, Xiaoyu Zhang, Wei Lin, Brian R Gastman, C David Pauza, Scott E Strome, Andrei I Chapoval.   

Abstract

Natural killer (NK) cells are innate effector lymphocytes that control the growth of major histocompatibility complex class I negative tumors. We show here that γδ T lymphocytes, expanded in vitro in the presence isopentenylpyrophosphate (IPP), induce NK cell-mediated killing of tumors that are usually resistant to NK cytolysis. The induction of cytotoxicity toward these resistant tumors requires priming of NK cells by immobilized human immunoglobulin G1 and costimulation through CD137L expressed on activated γδ T lymphocytes. This costimulation increases NKG2D expression on the NK-cell surface, which is directly responsible for tumor cell lysis. Moreover, culturing peripheral blood mononuclear cells with zoledronic acid, a γδ T lymphocyte activating agent, enhances NK-cell direct cytotoxicity and antibody-dependent cellular cytotoxicity against hematopoietic and nonhematopoietic tumors. Our data reveal a novel function of human γδ T lymphocytes in the regulation of NK cell-mediated cytotoxicity and provide rationale for the use of strategies to manipulate the CD137 pathway to augment innate antitumor immunity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20519625      PMCID: PMC3324253          DOI: 10.1182/blood-2009-07-234211

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  33 in total

Review 1.  [gamma][delta] cells: a right time and a right place for a conserved third way of protection.

Authors:  A C Hayday
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.

Authors:  A I Chapoval; J A Fuller; S G Kremlev; S J Kamdar; R Evans
Journal:  J Immunol       Date:  1998-12-15       Impact factor: 5.422

Review 3.  Natural killer cells, viruses and cancer.

Authors:  A Cerwenka; L L Lanier
Journal:  Nat Rev Immunol       Date:  2001-10       Impact factor: 53.106

4.  Gammadelta T cells for immune therapy of patients with lymphoid malignancies.

Authors:  Martin Wilhelm; Volker Kunzmann; Susanne Eckstein; Peter Reimer; Florian Weissinger; Thomas Ruediger; Hans-Peter Tony
Journal:  Blood       Date:  2003-03-06       Impact factor: 22.113

5.  B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production.

Authors:  A I Chapoval; J Ni; J S Lau; R A Wilcox; D B Flies; D Liu; H Dong; G L Sica; G Zhu; K Tamada; L Chen
Journal:  Nat Immunol       Date:  2001-03       Impact factor: 25.606

6.  Inducible costimulator costimulates cytotoxic activity and IFN-gamma production in activated murine NK cells.

Authors:  Kouetsu Ogasawara; Steven K Yoshinaga; Lewis L Lanier
Journal:  J Immunol       Date:  2002-10-01       Impact factor: 5.422

7.  Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer.

Authors:  Kishan J Pandya; Ajeet Gajra; Ghulam M Warsi; Eliza Argonza-Aviles; Solveig G Ericson; Antoinette J Wozniak
Journal:  Lung Cancer       Date:  2009-06-02       Impact factor: 5.705

8.  V delta 2+ gamma delta T lymphocytes are cytotoxic to the MCF 7 breast carcinoma cell line and can be detected among the T cells that infiltrate breast tumors.

Authors:  I Bank; M Book; M Huszar; Y Baram; I Schnirer; H Brenner
Journal:  Clin Immunol Immunopathol       Date:  1993-04

9.  Control of natural killer cell-mediated innate resistance against the intracellular pathogen Listeria monocytogenes by gamma/delta T lymphocytes.

Authors:  C H Ladel; C Blum; S H Kaufmann
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

10.  Gamma delta T cells provide an early source of interferon gamma in tumor immunity.

Authors:  Yunfei Gao; Wancai Yang; Meng Pan; Eileen Scully; Michael Girardi; Leonard H Augenlicht; Joe Craft; Zhinan Yin
Journal:  J Exp Med       Date:  2003-08-04       Impact factor: 14.307

View more
  85 in total

1.  ATP release and autocrine signaling through P2X4 receptors regulate γδ T cell activation.

Authors:  Monali Manohar; Mark I Hirsh; Yu Chen; Tobias Woehrle; Anjali A Karande; Wolfgang G Junger
Journal:  J Leukoc Biol       Date:  2012-06-29       Impact factor: 4.962

Review 2.  Combination strategies to enhance antitumor ADCC.

Authors:  Holbrook E Kohrt; Roch Houot; Aurélien Marabelle; Hearn Jay Cho; Keren Osman; Matthew Goldstein; Ronald Levy; Joshua Brody
Journal:  Immunotherapy       Date:  2012-05       Impact factor: 4.196

Review 3.  Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.

Authors:  Hamid Reza Mirzaei; Hamed Mirzaei; Sang Yun Lee; Jamshid Hadjati; Brian G Till
Journal:  Cancer Lett       Date:  2016-07-05       Impact factor: 8.679

4.  Cord blood Vγ2Vδ2 T cells provide a molecular marker for the influence of pregnancy-associated malaria on neonatal immunity.

Authors:  Cristiana Cairo; Nyaradzo Longinaker; Giulia Cappelli; Rose G F Leke; Manuel Mve Ondo; Rosine Djokam; Josephine Fogako; Robert J Leke; Bertrand Sagnia; Samuel Sosso; Vittorio Colizzi; C David Pauza
Journal:  J Infect Dis       Date:  2013-12-10       Impact factor: 5.226

Review 5.  Searching for "signal 2": costimulation requirements of γδ T cells.

Authors:  Julie C Ribot; Ana debarros; Bruno Silva-Santos
Journal:  Cell Mol Life Sci       Date:  2011-05-04       Impact factor: 9.261

Review 6.  Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside.

Authors:  Barbara Castella; Candida Vitale; Marta Coscia; Massimo Massaia
Journal:  Cell Mol Life Sci       Date:  2011-05-17       Impact factor: 9.261

7.  TNFSF9 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Pancreatic Cancer.

Authors:  Jiao Wu; Yunpeng Wang; Zheng Jiang
Journal:  J Gastrointest Cancer       Date:  2021-03

8.  Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.

Authors:  Holbrook E Kohrt; Ariane Thielens; Aurelien Marabelle; Idit Sagiv-Barfi; Caroline Sola; Fabien Chanuc; Nicolas Fuseri; Cécile Bonnafous; Debra Czerwinski; Amanda Rajapaksa; Erin Waller; Sophie Ugolini; Eric Vivier; François Romagné; Ronald Levy; Mathieu Bléry; Pascale André
Journal:  Blood       Date:  2013-12-10       Impact factor: 22.113

Review 9.  Depletion and dysfunction of Vγ2Vδ2 T cells in HIV disease: mechanisms, impacts and therapeutic implications.

Authors:  Haishan Li; Suchita Chaudhry; Suchita Chaudry; Bhawna Poonia; Yiming Shao; C David Pauza
Journal:  Cell Mol Immunol       Date:  2012-12-17       Impact factor: 11.530

10.  CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications.

Authors:  Matthew W Anderson; Shuchun Zhao; Aharon G Freud; Debra K Czerwinski; Holbrook Kohrt; Ash A Alizadeh; Roch Houot; Denize Azambuja; Irene Biasoli; José Carlos Morais; Nelson Spector; Hernan F Molina-Kirsch; Roger A Warnke; Ronald Levy; Yasodha Natkunam
Journal:  Am J Pathol       Date:  2012-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.